“Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials ” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s64. doi:10.25251/skin.6.supp.64.